Prostate Cancer - Results from #180

ERLEADA® (Apalutamide) Demonstrates Statistically Significant and Clinically Meaningful Improvement in Overall Survival Compared to Enzalutamide in Patients with Metastatic Castration-Sensitive Prostate Cancer October 7, 2024

Single-Hit and Multi-hit PIK3CA Short Variant Genomic Alterations in Clinically Advanced Prostate Cancer: A Genomic Landscape Study. October 7, 2024

Creatine supplementation does not add to resistance training effects in prostate cancer patients under androgen deprivation therapy: A double-blind randomized trial. October 7, 2024

Health-related quality of life of patients with prostate cancer initiating GnRH agonist therapy: the PRISME study. October 7, 2024

CDK12 loss drives prostate cancer progression, transcription-replication conflicts, and synthetic lethality with paralog CDK13. October 7, 2024

Surveillance after Focal Therapy - a Comprehensive Review. October 7, 2024

Patient Demographics and Major Adverse Cardiovascular Events after Androgen Deprivation Therapy for Prostate Cancer October 4, 2024

PSMA PET/CT patterns of recurrence after mono-brachytherapy in men with low and intermediate prostate cancer and subsequent management. October 4, 2024

Heterogeneous genetic architectures of prostate cancer susceptibility in sub-Saharan Africa. October 4, 2024

Prostate Specific Antigen and Prostate Cancer in Gender Affirming Hormone Therapy for Transgender or Nonbinary Individuals. October 4, 2024

Impact of Baseline Renal Insufficiency on Piflufolastat F-18 Performance and Investigation of Changes in Renal Function Following Piflufolastat F-18 Administration: Results From the OSPREY Trial. October 4, 2024

Prevalence and Factors Associated With Prostate Cancer Among Transgender Women. October 4, 2024

Integrated multi-omics assessment of lineage plasticity in a prostate cancer patient with brain and dural metastases. October 4, 2024

Pathological Assessment of Men with Grade Group 2 Prostate Cancer. October 3, 2024

Genomic Landscape in Prostate Cancer in a Latin American Population. October 3, 2024

Multicentric 68Ga-PSMA PET radiomics for treatment response assessment of 177Lu-PSMA-617 radioligand therapy in patients with metastatic castration-resistant prostate cancer. October 3, 2024

Real-world outcomes in patients with metastatic castration-resistant prostate cancer beyond progression after upfront androgen receptor signaling inhibitor. October 3, 2024

Germline and somatic testing for homologous repair deficiency in patients with prostate cancer (part 1 of 2). October 3, 2024

Clarity’s COBRA Study Selected as a Top-Rated Oral Presentation at Prestigious Industry Annual Meeting October 2, 2024

Testosterone Therapy in Men After Radical Prostatectomy for Organ-Confined, Low-Intermediate Prostate Cancer. October 2, 2024

Page 10 of 1437